Mobile Health Interventions for Medication Adherence Among PLWH

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
HIV/AIDSSmokingSmoking CessationHIV
Interventions
DRUG

Varenicline

All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84

DEVICE

Mobile phone application

Participants randomized to 2 of the 3 study groups will receive a mobile phone application designed to improve adherence to medication. The app has a number of functions, including: a) reminders to take medication; b) information about coping strategies for dealing with side effects and withdrawal symptoms; c) provision of a personalized graphical display of treatment progress (e.g., adherence, side effects); d) camera-based verification of having taken medication.

BEHAVIORAL

Contingency management

Participants randomized to 1 of the 3 study groups will receive monetary reinforcement contingent upon verified medication adherence behaviors. Participants in the other 2 groups will be yoked to a participant in the CM group so that they also have a chance of earning monetary reinforcers, though not contingent upon their own behaviors.

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Duke University

OTHER

NCT04191278 - Mobile Health Interventions for Medication Adherence Among PLWH | Biotech Hunter | Biotech Hunter